Prognostic Value of 1p, 19q, 9p, 10q, and EGFR-FISH Analyses in Recurrent Oligodendrogliomas

Journal of Neuropathology and Experimental Neurology

Volumn 63, Issue 4, 2004, Pages 314-322

  Fallon, Kenneth B ^a   Palmer, Cheryl A ^a   Roth, Kevin A ^a   Nabors, L Burton ^a   Wang, Wenquan ^b   Carpenter, Mark ^b   Banerjee, Ruma ^c   Forsyth, Peter ^e   Rich, Keith ^d   Perry, Arie ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e UNIVERSITY OF CALGARY   (Canada)

Author keywords

Fluorescence in situ hybridization (FISH); Gene amplification; Gene deletion; Oligodendroglioma; Recurrence; Survival; Tumor genetics

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOME 10Q; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME 9P; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE AMPLIFICATION; GENE DELETION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH; TUMOR RECURRENCE;

EID: 12144290789     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/63.4.314     Document Type: Article

References (28)

1. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-79
2. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas. astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000;18:636-45
3. Bauman GS, Ino Y, Ueki K, et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 2000;48:825-30
4. van den Bent MJ, Keime-Guibert F, Brandes AA, et al. Temozolamide chemotherapy in recurrent oligodendroglioma. Neurology 2001;57:340-42
5. Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis. Clin Canc Res 2001;7:839-45
6. Burger PC, Pearl DK, Aldape K, et al. Small cell architecture - A histological equivalent of EGFR amplification in glioblastoma multiforme? J Neuropathol Exp Neurol 2001;1099-1104
7. Perry A, Fuller CE, Banerjee R, Brat DJ, Scheithauer BW. Ancillary FISH analysis for 1p and 19q status: Preliminary observations in 287 gliomas and oligodendroglioma mimics. Front Biosci 2003;8:a1-a9
8. Reifenberger G, Louis DN. Oligodendroglioma: Toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 2003;62:111-26
9. Reifenberger G, Kros JM, Burger PC, Louis DN, Collins VP. World Health Organization Classification of Tumors. Pathology and genetics. Tumors of the nervous system 2000;56-70
10. Fuller CE, Wang H, Zhang W, Fuller G, Perry A. High-throughput molecular profiling of high-grade astrocytomas: The utility of fluorescent in situ hybridization on tissue microarrays (TMA-FISH). J Neuropathol Exp Neurol 2002;61:1078-84
11. Perry A. Oligodendroglial neoplasms: Current concepts, misconceptions, and folklore. Adv Anat Pathol 2001;8:183-99
12. Burger PC, Minn AY, Smith JS, et al. Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Mod Pathol 2001;14:842-53
13. Sato K, Schauble B, Kleihues P, Ohgaki H. Infrequent alterations of the p15, p16, CDK4, and cyclin D1 genes in non-astrocytic human brain tumors. Int J Cancer 1996;66:305-88
14. Smith JS, Jenkins RB. Genetic alterations in adult diffuse glioma: Occurrence, significance, and prognostic implications. Front Biosci 2000;5:d213-d231
15. Bortolotto S, Chiado-Piat L, Cavalla P, et al. CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas. Int J Cancer 2000;88:554-57
16. Miettinen H, Kononen J, Sallinen P, et al. CDKN2/p16 predicts survival in oligodendrogliomas: Comparison with astrocytomas. J Neurooncol 1999;41:205-11
17. Duerr EM, Rollbrocker B, Hayashi Y, et al. PTEN mutations in gliomas and glioneuronal tumors. Oncogene 1998;16:2259-64
18. Hayashi Y, Ueki K, Waha A, Wiestler OD, Louis DN, von Deimling A. Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol 1997;7:871-75
19. Schmidt EE, Ichimura K, Reifenberger G, Collins VP. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Canc Res 1994;54:6321-24
20. Bigner SH, Matthews MR, Rasheed BK, et al. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 1999;155:375-86
21. Zhou XP, Li YJ, Hoang-Xuan K, et al. Mutational analysis of the PTEN gene in gliomas: Molecular and pathological correlations. Int J Cancer 1999;84:150-54
22. Mollenhauer J, Wiemann S, Scheurlen W, et al. DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours. Nat Genet 1997;17:32-39
23. Sanson M, Leuraud P, Aguirre-Cruz L, et al. Analysis of loss of chromosome 10q, DMBT1 homozygous deletions, and PTEN mutations in oligodendrogliomas. J Neurosurg 2002;97:1397-401
24. Sasaki H, Betensky RA, Cairncross JG, Louis DN. DMBT1 polymorphisms: Relationship to malignant glioma tumorigenesis. Cancer Res 2002;62:1790-96
25. Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG, Louis DN. PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol 2001;159:359-67
26. McLendon RE, Wikstrand CJ, Matthews MR, Al-Baradei R, Bigner SH, Bigner DD. Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor. J Histochem Cytochem 2000;48:1103-10
27. Reifenberger J, Reifenberger G, Ichimura K, Schmidt EE, Wechsler W, Collins VP. Epidermal growth factor receptor expression in oligodendroglial tumors. Am J Pathol 1996;149:29-35
28. Weiss WA, Burns MJ, Hackett C, et al. Genetic determinants of malignancy in a mouse model for oligodendroglioma. Canc Res 2003;63:1589-95